Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.
Fiche publication
Date publication
juin 2017
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier
Tous les auteurs :
Bröckelmann PJ, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M, McCall SJ, Morschhauser F, Fuchs M, Borchmann P, Moskowitz CH, Engert A
Lien Pubmed
Résumé
Novel agents are changing the treatment of relapsed or refractory Hodgkin lymphoma (HL). Nevertheless, high-dose chemotherapy and autologous stem-cell transplantation (ASCT) are considered standard of care in eligible patients. To identify patients who could benefit most from novel therapeutic approaches, we investigated a comprehensive set of risk factors (RFs) for survival after ASCT.
Mots clés
Adult, Aged, Female, Hematopoietic Stem Cell Transplantation, Hodgkin Disease, therapy, Humans, Male, Middle Aged, Prognosis, Proportional Hazards Models, Recurrence, Risk Factors, Survival Analysis
Référence
Ann. Oncol.. 2017 Jun 1;28(6):1352-1358